Last Updated on October 11, 2024 by The Health Master
AstraZeneca Pharma India said it has received approval from the Drugs Controller General of India (DCGI) to import heart failure treatment drug Dapagliflozin tablets.
The company has received permission from the DCGI to import pharmaceutical formulations of a new drug for sale, the drug firm said in a regulatory filing.
Dapagliflozin tablets are indicated for the treatment of heart failure in adults, it added.
The receipt of this permission paves the way for the launch of the product in India for the specified indication, subject to the receipt of related statutory approvals and licenses, it said.
Shares of the company ended 0.86 per cent down at Rs 3,769.40 apiece on the BSE.
DCGI gives approval for Dupilumab to treat Atopic Dermatitis
DCGI approves first indigenously developed animal-derived Class D Biomedical Device
DCGI approves Covovax as booster dose
Bar Code or QR Code: Implementation mandated for Top 300 Brand Drugs from August 1, 2023
USFDA concludes inspection at Eugia Pharma with zero observation
The need for uniform pricing of Medical Devices and Surgical Products
USFDA gives approval for Plerixafor injection
Types of inspections done by USFDA: Read in detail
An overview of Legislative Bills related to Pharma in the ongoing Parliament Session
Drug alert: 48 out of 1273 samples declared as NSQ in June 2023
Indian Pharma Industry wants to end multiple inspections by USFDA
Govt asks Medical Stores not to sell painkillers without prescription: Delhi
AHUs, Air Types, Air Changes and their Functions in Pharma Industry
